A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
暂无分享,去创建一个
G. Stone | S. Ellis | C. O'shaughnessy | J. Popma | D. Cox | J. Hermiller | M. Turco | M. Russell | R. Caputo | Joel D Greenberg | P. Bergin | J. T. Mann | J. Mann | Joel Greenberg
[1] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[2] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[3] Mary E. Russell,et al. TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.
[4] M. Eisenberg,et al. Coated stents for the prevention of restenosis: Part I. , 2002, Circulation.
[5] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[6] P. Serruys,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.
[7] C. Morillo,et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. , 2001, Journal of the American College of Cardiology.
[8] R. Virmani,et al. Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.
[9] T. Fojo,et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity , 2001, Oncogene.
[10] A. Küttner,et al. Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter , 2001, Basic Research in Cardiology.
[11] B. McManus,et al. Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries. , 2001, Journal of vascular and interventional radiology : JVIR.
[12] G. Mintz,et al. Coronary in-stent restenosis - predictors, treatment and prevention. , 2000, European heart journal.
[13] J. Testa,et al. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. , 2000, Cancer research.
[14] A. Baumbach,et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. , 2000, Journal of the American College of Cardiology.
[15] G. Stone,et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.
[16] E. DeLong,et al. Acute and long-term cost implications of coronary stenting. , 1999, Journal of the American College of Cardiology.
[17] R. Virmani,et al. Pathology of acute and chronic coronary stenting in humans. , 1999, Circulation.
[18] J. Tobis,et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis. , 1998, Journal of the American College of Cardiology.
[19] T. Cruz,et al. Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes. , 1998, Arthritis and rheumatism.
[20] T. Fojo,et al. Microtubule-interfering Agents Activate c-Jun N-terminal Kinase/Stress-activated Protein Kinase through Both Ras and Apoptosis Signal-regulating Kinase Pathways* , 1998, The Journal of Biological Chemistry.
[21] M. Hadamitzky,et al. Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.
[22] A. Küttner,et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.
[23] H. Burt,et al. Calcium pyrophosphate dihydrate crystals activate MAP kinase in human neutrophils: inhibition of MAP kinase, oxidase activation and degranulation responses of neutrophils by taxol , 1997, Immunology.
[24] G. Viale,et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] E. Lakatta,et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. , 1995, The Journal of clinical investigation.
[26] W Rutsch,et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.
[27] P. Teirstein,et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.
[28] J. Reiber,et al. A new approach for the quantification of complex lesion morphology: the gradient field transform; basic principles and validation results. , 1994, Journal of the American College of Cardiology.
[29] J. Gallin,et al. Effects of taxol on human neutrophils. , 1982, Journal of immunology.